An open, randomised, comparative, multicentre study of the immunogenicity and safety of ProQuad [MMR-varicella zoster virus vaccine] when administered by intramuscular (IM) route or subcutaneous (SC) route to healthy children aged 12 to 18 months.

Trial Profile

An open, randomised, comparative, multicentre study of the immunogenicity and safety of ProQuad [MMR-varicella zoster virus vaccine] when administered by intramuscular (IM) route or subcutaneous (SC) route to healthy children aged 12 to 18 months.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; MMR-varicella zoster virus vaccine (Primary)
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 01 Jul 2008 Actual end date changed from 1 May 07 to 1 January 2008, reported by Clinicaltrals.gov.
    • 27 Oct 2007 Status changed from in progress to completed.
    • 01 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top